Predictive Oncology (POAI): Market Capitalization-to-Revenue Ratio

Predictive Oncology is implementing automated robotic cells for equipment calibration and control. The P/S multiple visualizes market expectations, where the value of 27.60 serves as the current indicator. The company generates revenue through B2B subscriptions to its PeDAL platform, accelerating the search for therapies. The business advantage lies in the utilization of AI and the largest dataset of tumors to predict cellular responses.

The P/S ratio reflects the relationship between the market capitalization of Predictive Oncology (POAI) and its annual revenue, determining the cost of each dollar of sales. By analyzing the fundamental P/S on the GURU.Markets platform, an investor assesses whether the business is overvalued or if there is a potential undervaluation. This metric measures the efficiency of asset monetization relative to market expectations. The stability of this valuation for Predictive Oncology (POAI) is supported by its proprietary biobank and computing center in Pennsylvania.